Mode
Text Size
Log in / Sign up

Zinc supplementation raises plasma zinc and lowers insulin resistance in diabetesZinc supplements may improve insulin resistance in people with diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider zinc supplementation for metabolic improvements, but monitor LDL cholesterol given the uncertain clinical relevance.

This meta-analysis pooled data from randomized controlled trials to evaluate the effects of zinc supplementation in individuals with diabetes, gestational diabetes, or prediabetes. The analysis included 1023 participants and assessed multiple metabolic and inflammatory outcomes.

Zinc supplementation significantly increased plasma zinc concentrations (MD = 7.80, 95% CI 4.33 to 11.26). It also reduced serum insulin (MD = -2.50, 95% CI -4.69 to -0.31) and HOMA-IR (MD = -1.10, 95% CI -2.05 to -0.15), indicating improved insulin resistance.

Lipid changes were mixed: total cholesterol decreased (MD = -5.70, 95% CI -7.50 to -3.89), but LDL cholesterol increased (MD = 3.46, 95% CI 1.48 to 5.43). Inflammatory and oxidative stress markers improved, with reductions in C-reactive protein (SMD = -0.91, 95% CI -1.43 to -0.38) and malondialdehyde (SMD = -0.76, 95% CI -1.34 to -0.18), and an increase in total antioxidant capacity (SMD = 1.79, 95% CI 0.68 to 2.91).

The authors note that the clinical relevance of the LDL cholesterol increase is uncertain. Adverse events and follow-up duration were not reported. As a meta-analysis, these findings represent associations and should be interpreted with caution.

How this fits prior evidence

This meta-analysis extends prior coverage on micronutrient supplementation in metabolic conditions. It confirms the mixed results seen with micronutrients in colorectal cancer, showing both benefits and potential harms (LDL increase). It also aligns with the context-dependent evidence for antioxidants in neurodegenerative diseases, supporting a nuanced view of supplementation. The findings on insulin resistance and inflammatory markers add to the evidence base linking metabolic interventions to improved outcomes, but the LDL increase warrants caution.

Managing blood sugar and inflammation is a constant challenge for people living with diabetes, gestational diabetes, or prediabetes. A large review of data involving over 1,000 people looked at how zinc supplements might affect these conditions. The findings suggest that taking zinc could lead to measurable improvements in how the body handles insulin and manages internal stress.

The study found that zinc supplementation was linked to lower insulin resistance and lower levels of serum insulin. It also showed a decrease in C-reactive protein, which is a marker for inflammation in the body, and a reduction in malondialdehyde, a marker of oxidative stress. Additionally, patients saw an increase in their total antioxidant capacity.

While the results are promising for managing metabolic health, there are some nuances. For example, the study noted an increase in LDL cholesterol, but it is unclear if this change is clinically significant. Because this is a meta-analysis of various trials, the results show a clear association but do not provide a definitive guarantee for every individual.

What this means for you:
Zinc supplementation is linked to better insulin resistance and lower inflammation in people with diabetes.

Common questions

Can zinc help with insulin resistance?

Yes, the data shows that zinc supplementation was associated with a reduction in HOMA-IR, which is a measure of insulin resistance. It also led to a decrease in serum insulin levels for those with diabetes, gestational diabetes, or prediabetes.

Does zinc affect inflammation in people with diabetes?

The study found that zinc supplementation was associated with a decrease in C-reactive protein. This is a common marker used to measure inflammation in the body. It also showed a reduction in malondialdehyde, which helps track oxidative stress.

Are there any risks to taking zinc for diabetes?

The study noted that zinc supplementation was associated with an increase in LDL cholesterol. However, the researchers noted that the clinical relevance of this specific increase is uncertain. You should talk to your doctor before starting any new supplement.

Study Details

Study typeMeta analysis
Sample sizen = 1,023
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
OBJECTIVES: Diabetes mellitus (DM) is a chronic metabolic disorder characterized by insulin resistance, impaired insulin secretion, and increased cardiometabolic and inflammatory burden. Zinc plays a key biological role in insulin synthesis, storage, signalling and antioxidant defence; however, the clinical relevance and consistency of zinc supplementation effects in diabetes remain uncertain. METHODS: A systematic search of PubMed/MEDLINE, Web of Science, Scopus, CINAHL and Google Scholar was conducted to identify randomized controlled trials (RCTs) assessing zinc supplementation in individuals with diabetes, gestational diabetes or prediabetes. RESULTS: Eighteen RCTs involving 1023 participants met the eligibility criteria. Zinc supplementation significantly increased plasma zinc concentrations (MD = 7.80; 95% CI 4.33 to 11.26) and improved insulin resistance, as reflected by reductions in serum insulin (MD = -2.50; 95% CI -4.69 to -0.31) and HOMA-IR (MD = -1.10; 95% CI -2.05 to -0.15). Total cholesterol decreased modestly but significantly (MD = -5.70; 95% CI -7.50 to -3.89), representing a relatively small absolute reduction, while LDL cholesterol showed a modest increase (MD = 3.46; 95% CI 1.48 to 5.43), although the clinical relevance of this finding remains uncertain. Inflammatory and oxidative stress markers improved, including reductions in C-reactive protein (SMD = -0.91; 95% CI -1.43 to -0.38) and malondialdehyde (SMD = -0.76; 95% CI -1.34 to -0.18), alongside an increase in total antioxidant capacity (SMD = 1.79; 95% CI 0.68 to 2.91). CONCLUSIONS: Zinc supplementation was associated with improvements in insulin resistance, inflammatory status and oxidative stress markers in individuals with diabetes. TRIAL REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42025638646.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.